US · NKTR · BIOTECHNOLOGY
Nektar Therapeutics (NKTR) intrinsic value and stock valuation
$30.20as of 2026-11-21 · Mkt cap 2.1B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Nektar Therapeutics DCF and intrinsic value
InvestorsCraft values NKTR with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from NKTR’s statements →
Nektar Therapeutics Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M |
| Operating income | -$-130.77M | -$-105.2M | -$-137.43M | -$-240.24M | -$-446.1M |
| Net income | -$-164.08M | -$-118.96M | -$-276.06M | -$-368.2M | -$-523.84M |
| EPSd | -$-9.73M | -$-8.68M | -$-21.79M | -$-29.5M | -$-42.87M |
| Operating cash flow | -$-208.51M | -$-175.71M | -$-192.61M | -$-304.01M | -$-412.66M |
| Capital expenditure | -$-170K | -$-1.47M | -$-860K | -$-5.68M | -$-14.99M |
| Free cash flow | -$-208.68M | -$-177.18M | -$-193.47M | -$-309.68M | -$-427.65M |
| Total assets | $280.4M | $303.9M | $398M | $710.6M | $1.12B |
| Total debt | $148.9M | $102.6M | $117.8M | $131.5M | $143.2M |
| Net debt | $133.8M | $58.3M | $82.5M | $43.3M | $118M |
| Total equity | $89.8M | $60.7M | $131M | $366.6M | $679.5M |
| Cash and short-term investments | $245.8M | $255.2M | $303.6M | $505M | $734M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M |
| Cost of revenue | $0.00 | $30.7M | $36.6M | $21.6M | $24.9M |
| Gross profit | $55.2M | $67.7M | $53.5M | $70.4M | $77M |
| Research and development expenses | $117.3M | $120.9M | $114.2M | $218.3M | $400.3M |
| Selling, general and administrative expenses | $68.7M | $76.8M | $77.4M | $92.3M | $122.8M |
| Other expenses | $0.00 | -$-24.72M | -$-680K | $0.00 | $0.00 |
| Operating expenses | $186M | $172.9M | $190.9M | $310.7M | $523.1M |
| Cost and expenses | $186M | $203.6M | $227.6M | $332.3M | $548M |
| Interest income | $10.4M | $14.5M | $19M | $6.78M | $2.73M |
| Interest expense | $26.2M | $28.1M | $25.3M | $28.9M | $47.3M |
| Depreciation and amortization | $1.03M | $4.39M | $7.82M | $12.2M | $14.2M |
| Ebitda | -$-137M | -$-86.7M | -$-243.11M | -$-323.87M | -$-461.82M |
| Operating income | -$-130.77M | -$-105.2M | -$-137.43M | -$-240.24M | -$-446.1M |
| Total other income/expenses, net | -$-33.44M | -$-14M | -$-138.83M | -$-124.75M | -$-77.18M |
| Income before tax | -$-164.21M | -$-119.2M | -$-276.26M | -$-364.98M | -$-523.28M |
| Income tax expense | -$-140K | -$-240K | -$-200K | $3.21M | $560K |
| Net income | -$-164.08M | -$-118.96M | -$-276.06M | -$-368.2M | -$-523.84M |
| Weighted average shares outstanding | $16.9M | $13.7M | $12.7M | $12.5M | $12.2M |
| Weighted average diluted shares outstanding | $16.9M | $13.7M | $12.7M | $12.5M | $12.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $245.8M | $255.2M | $303.6M | $505M | $734M |
| Net receivables | $1.78M | $1.61M | $2.25M | $8.4M | $22.5M |
| Inventory | $0.00 | $0.00 | $16.1M | $19.2M | $15.8M |
| Total current assets | $266.3M | $261.3M | $330.7M | $546M | $795.6M |
| Property, plant and equipment, net | $5M | $11.8M | $36.9M | $85.9M | $177.5M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $76.5M | $76.5M |
| Long-term investments | $3.49M | $26.1M | $25.8M | $0.00 | $64.8M |
| Total non-current assets | $14.1M | $42.6M | $67.3M | $164.6M | $321.6M |
| Total assets | $280.4M | $303.9M | $398M | $710.6M | $1.12B |
| Accounts payable | $10.8M | $11.6M | $9.85M | $13M | $9.75M |
| Short-term debt | $20.5M | $19.9M | $19.3M | $18.7M | $17.4M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $53.5M | $61.4M | $51.3M | $68.2M | $85.2M |
| Long-term debt | $128.4M | $82.7M | $98.5M | $112.8M | $125.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $137M | $181.7M | $215.8M | $275.8M | $352.5M |
| Capital lease obligations | $65.3M | $102.6M | $117.8M | $131.5M | $143.2M |
| Total liabilities | $190.6M | $243.1M | $267.1M | $344M | $437.7M |
| Common stock | $0.00 | $20K | $20K | $20K | $20K |
| Retained earnings | -$-3.76B | -$-3.6B | -$-3.48B | -$-3.2B | -$-2.83B |
| Accumulated other comprehensive income (loss) | $20K | $60K | $80K | -$-6.91M | -$-4.16M |
| Total equity | $89.8M | $60.7M | $131M | $366.6M | $679.5M |
| Total investments | $234.1M | $237.1M | $294.2M | $416.8M | $773.6M |
| Total debt | $148.9M | $102.6M | $117.8M | $131.5M | $143.2M |
| Net debt | $133.8M | $58.3M | $82.5M | $43.3M | $118M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-164.08M | -$-118.96M | -$-276.06M | -$-368.2M | -$-523.84M |
| Depreciation and amortization | -$-4.49M | $4.39M | $7.82M | $13M | $14.2M |
| Stock-based compensation | $12.7M | $21.6M | $33.4M | $57.3M | $94.7M |
| Change in working capital | -$-37.02M | -$-6.24M | -$-19.8M | $490K | -$-23.08M |
| Accounts receivable | $0.00 | -$-3.04M | $4.78M | $16.5M | $12.4M |
| Inventory | $0.00 | $500K | $700K | -$-3.4M | -$-510K |
| Accounts payable | -$-620K | $2.67M | -$-2.88M | $3.1M | -$-11.69M |
| Net cash provided by operating activities | -$-208.51M | -$-175.71M | -$-192.61M | -$-304.01M | -$-412.66M |
| Investments in property, plant and equipment | -$-170K | -$-1.47M | -$-860K | -$-5.68M | -$-14.99M |
| Acquisitions, net | -$-700K | $65.4M | $0.00 | $13.2M | -$-217.77M |
| Net cash used for investing activities | -$-1.2M | $142.6M | $139.6M | $365.8M | $202.8M |
| Common stock issued | $180.6M | $30.1M | $30K | $760K | $33.2M |
| Common stock repurchased | $0.00 | -$-3M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $180.6M | $42.1M | $30K | $1.51M | $36.2M |
| Net change in cash | -$-29.14M | $8.97M | -$-52.95M | $63M | -$-173.74M |
| Cash at end of period | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M |
| Operating cash flow | -$-208.51M | -$-175.71M | -$-192.61M | -$-304.01M | -$-412.66M |
| Capital expenditure | -$-170K | -$-1.47M | -$-860K | -$-5.68M | -$-14.99M |
| Free cash flow | -$-208.68M | -$-177.18M | -$-193.47M | -$-309.68M | -$-427.65M |
Line items
Line items
Line items
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
- CEO
- Howard W. Robin
- Employees
- 63
- Beta
- 1.14
Included in
Explore
Frequently asked questions
What is the intrinsic value of Nektar Therapeutics (NKTR)?
Nektar Therapeutics (NKTR) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NKTR undervalued?
NKTR trades at a price of $30.20 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.